Moving the needle on vaccine preventable diseases.

MMGH uses a unique combination of rigorous academic research, tailor-made teams, specialist knowledge, industry-specific experience, state-of-the-art tools and independent thinking, to provide trusted advice and implementable solutions for programmes and products related to Vaccine Preventable Diseases, and Neglected Tropical Diseases, within the public health sphere.

Filters

Focus Areas
Projects - Focus Areas
  • Access
  • Evaluation
  • Implementation
  • Policy & Strategy
Vaccine Preventable Diseases
Projects - Vaccine Preventable Diseases
  • Cholera
  • COVID-19
  • Diphtheria
  • Enteric Fever
  • Human Papillomavirus
  • Influenza
  • Japanese Encephalitis
  • Leishmaniasis
  • Measles-Rubella
  • Meningitis
Search
Sort By (Projects)
2021 — 2021

Seasonal influenza vaccine value proposition: Definition of use cases and...

As part of the global effort to conduct a full-value of seasonal influenza vaccine assessment, MMGH supported WHO to conduct a scoping assessment and literature review of past, ongoing and…
Client
World Health Organisation (WHO)
2021 — Ongoing

Support to WHO SAGE Secretariat...

MMGH is supporting the SAGE secretariat with summarizing SAGE deliberations and with drafting and finalizing the report of the regular SAGE meeting in October 2021.
Client
World Health Organisation (WHO)
2021 — Ongoing

Rapid Vaccine Manufacturing Diagnostic Study...

MMGH is assisting the Inter-American Development Bank to prepare a rapid vaccine supply diagnostic study in support of work aimed at generating capacities in the countries that integrate PROSUR to…
Client
Inter American Deelopment Bank
2021 — 2021

Regional manufacturing of COVID-19 vaccines...

MMGH is assisting the Asian Development Bank's Interdepartmental Vaccine Manufacturing Task Force to assess demand for COVID-19 vaccines and vaccine manufacturing capacity in developing countries in Asia and Pacific.
Client
Asian Development Bank
2021 — Ongoing

Seasonal influenza vaccine value proposition: Development of a generic use...

MMGH is supporting the US CDC and WHO to validate preliminary use cases and country archetypes previously developed for seasonal influenza vaccines. MMGH is conducting staekholder surveys, interviews and workshops…
Client
Centers for Disease Control and Prevention (CDC)
2021 — Ongoing

Strengthen Philippines Vaccine Manufacturing...

In collaboration with a team of experts, MMGH is assisting The Asian Development Bank (ADB) to support the Department of Health and the Research Institute for Tropical Medicine (RITM) from…
Client
Asian Development Bank
2020 — Ongoing

Development of European Region Immunisation Agenda 2030...

MMGH is supporting the WHO European Regional Office (EURO) in developing the Regional Immunisation Agenda for the period 2021-2030 in alignment with the Global Immunisation Agenda 2030 (IA2030).
Client
World Health Organization (WHO)
Image Credit: Swarnavo Chakrabarti
2020 — 2020

Definition of barriers and drivers of an effective vaccine development...

MMGH supported the Wellcome Trust in mapping and sizing the factors influencing vaccine developers’ decisions in progressing along the development pathway: from transition into Phase II clinical trials to early…
Client
Wellcome Trust
Image Credit: Gavi, the Vaccine Alliance
2020 — 2021

COVID-19 Support to Gavi, the Vaccine Alliance...

MMGH supported Gavi, the Vaccine Alliance by documenting and synthesizing its key decisions related to the COVAX Facility and COVAX Advance Market Commitment (AMC). Activities include a desk review, key…
Client
Gavi, The Vaccine Alliance
Image Credit: Akiko Harayama
2020 — Ongoing

Definition of prioritised research agenda to support the implementation of...

In collaboration with the Global Task Force on Cholera Control (GTFCC), MMGH developed a Research Agenda aligned to the Roadmap. The Research Agenda serves as a guide for the allocation…
Client
Wellcome Trust
Image Credit: Helena Spongenberg
2020 — Ongoing

Development of the European Immunisation Agenda 2030 (EIA2030) Operational Framework...

MMGH is supporting the WHO European Regional Office (EURO) in developing its operational framework for its European Immunisation Strategy 2030 (EIA2030 Strategy). The operational framework will focus on how the…
Client
World Health Organisation (WHO)
Image Credit: Yasmina Guerda
2019 — 2019

Guidance to support countries introducing health worker influenza vaccination...

MMGH supported the WHO Initiative for Vaccine Research (IVR) in reviewing the scientific evidence on health worker (HW) influenza vaccination, collating currently available immunisation strategies, and synthesising a practical introduction…
Client
World Health Organisation (WHO)
Image Credit: Unicef
2019 — 2020

Measles and Rubella Strategic Framework 2021-2030...

MMGH supported the Measles & Rubella Initiative (M&RI) in the definition of the post-2020 global strategic framework in alignment with the Immunisation Agenda 2030 (IA2030). After performing a situational analysis…
Client
Measles and Rubella Initiative
2019 — 2019

Redesign of the Eliminate Yellow Fever programme governance and work...

MMGH supported the Eliminate Yellow Fever (EYE) Secretariat at WHO in streamlining programme governance and defining the general lines of action to serve as the foundation of a three-year multi-agency…
Client
World Health Organisation (WHO)
2019 — 2019

Human Papillomavirus (HPV) affordability analysis...

MMGH supported the WHO Department of Immunisation and Biologicals (IVB) in defining a logical framework to assess the barriers to access human papillomavirus (HPV) vaccine in middle-income countries, with a…
Client
World Health Organisation (WHO)
2018 — 2018

Development of WHO’s pneumococcal vaccine position paper...

MMGH supported WHO in drafting the position paper on Pneumococcal conjugate vaccines (PCV) in infants and children under 5 years of age. The position paper summarises the evidence on the…
Client
World Health Organisation (WHO)
Image Credit: Yasmina Guerda
2018 — 2018

Development of operational guidelines on equity in immunisation...

MMGH supported the WHO Regional Office for Europe in drafting operational guidelines for programme managers to measure inequities in immunisation, with a focus on understanding the root causes and implementing…
Client
World Health Organisation (WHO)
Image Credit: Akiko Harayama
2018 — 2018

Investment case for the Ending Cholera: A Global Roadmap to...

MMGH supported the Global Task Force on Cholera Control (GTFCC), on a Bill & Melinda Gates Foundation funded grant, in assessing and estimating the financial needs and benefits of the…
Client
Global Task Force on Cholera Control
Image Credit: MMGH/Carsten Mantel
2018 — 2018

Strategy for accelerated control of Japanese encephalitis in South East...

MMGH supported the WHO Regional Office for the Western Pacific in developing a guide for accelerating control of Japanese encephalitis (JE). The guide outlines regional targets, defines strategies and activities…
Client
World Health Organisation (WHO)
2017 — 2017

Development of the WHO’s typhoid vaccines position paper...

MMGH supported the WHO Initiative for Vaccine Research (IVR) in facilitating a Strategic Advisory Group of Experts on Immunisation (SAGE) Working Group review of the scientific evidence and programmematic considerations…
Client
World Health Organisation (WHO)
2017 — 2017

Immunisation Practices Advisory Committee (IPAC) ToR revision...

MMGH supported the WHO Immunisation Practices Advisory Committee (IPAC) Secretariat in revising the committee’s Terms of Reference (ToR). Based on information collected by MMGH during a series of in-depth stakeholder…
Client
World Health Organisation (WHO)
Image Credit: MMGH/Carsten Mantel